# Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in AF

Study · id `cardio:ct-nct02387229` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02387229](<https://clinicaltrials.gov/study/NCT02387229>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02387229

Browse, organ or system: Heart; Brain  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 1238 participants.

## Technical summary

Registry record NCT02387229. Randomized; quadruple masking; primary purpose prevention. Start 2015-03 (actual); primary completion 2024-05-18 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 1238 participants (enrolled count; ClinicalTrials.gov record NCT02387229, source copy `cardio:ctgov-nct02387229-2025-06-15`, retrieved 2026-10-26)
- Started: 2015-03 (actual) (ClinicalTrials.gov record NCT02387229, source copy `cardio:ctgov-nct02387229-2025-06-15`, retrieved 2026-10-26)
- Primary completion: 2024-05-18 (actual) (ClinicalTrials.gov record NCT02387229, source copy `cardio:ctgov-nct02387229-2025-06-15`, retrieved 2026-10-26)
- Completion: 2024-05-18 (actual) (ClinicalTrials.gov record NCT02387229, source copy `cardio:ctgov-nct02387229-2025-06-15`, retrieved 2026-10-26)
- Countries: Canada (ClinicalTrials.gov record NCT02387229, source copy `cardio:ctgov-nct02387229-2025-06-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02387229-2025-06-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in AF
- Acronym: BRAIN-AF
- Condition: ATRIAL FIBRILLATION
- Intervention (Drug): Rivaroxaban
- Intervention (Other): standard of care
- Lead sponsor: Montreal Heart Institute
- Lead sponsor class: OTHER
- Collaborator: Canadian Stroke Prevention Intervention Network
- Collaborator class: OTHER
- Collaborator: The Montreal Health Innovations Coordinating Center (MHICC)
- Collaborator class: OTHER
- Collaborator: Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
- Collaborator class: INDUSTRY
- Collaborator: Montreal Heart Institute Foundation
- Collaborator class: UNKNOWN
- Collaborator: Canadian Institutes of Health Research (CIHR)
- Collaborator class: OTHER\_GOV
- Collaborator: Hewitt Foundation
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record: Rivaroxaban (`cardio:rivaroxaban`)
- Registry lists this organization as the lead sponsor: Montreal Heart Institute (`cardio:org-montreal-heart-institute`)
- Registry lists this organization as a collaborator: The Montreal Health Innovations Coordinating Center (MHICC) (`cardio:org-the-montreal-health-innovations-coordinating-center-mhicc`)
- Registry lists this organization as a collaborator: Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma (`cardio:org-bayer-healthcare-pharmaceuticals-inc-bayer-schering-pharma`)
- Registry lists this organization as a collaborator: Canadian Institutes of Health Research (CIHR) (`cardio:org-canadian-institutes-of-health-research-cihr`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Anticoagulation to prevent ischemic stroke and neurocognitive impairment in atrial fibrillation: the BRAIN-AF randomized clinical trial (`cardio:pubmed-41501492`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: e316e4dae4f02c4792ca90aaacc1aa34e1fcab0809703bde250056e055701af7
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
